HomeAfter some pharmaceutical companies can make huge amounts of money from sales.
COVID-19 Vaccine
During the global epidemic more than 2 years ago
But when vaccination is distributed to many people around the world.
until it began to alleviate the severe patient problems from COVID-19
And led to the opening of the country to accept tourists in many countries.
“The need for urgent supply of vaccines in large quantities
And do not mind the price, "
so it gradually subsides every moment.
And this is probably
The “starting point”
that makes pharmaceutical companies
need to start adjusting to prepare for
“There is a sharp drop in revenue that analysts call the 'COVID cliff' in 2023.
1. Pfizer Company (Pfizer):
In the past
year 2022 ,
"Pfizer"
made the highest revenue ever since the company opened.
By earning a total of
100,300 million US dollars!
(About 3.3 trillion baht, exchange rate as of February 7, 23)
by the number
100,300 million US dollars
That 's 23%
higher than the
2021
revenue of $81,288 million!
(2020 Revenue: $41,651 million)
While EPS was
$5.47, or a 42% increase
year over year.
As for the figure , the company's net profit in 2022 is
$ 31,372 million (about 1.05 trillion baht, exchange rate as of February 7, 23)
, which is higher than the net profit of 2021, which was
$ 21,979 million ( About 7.3 billion baht, exchange rate as of February 7, 23) up to 43%!
However, for
the year 2023
, Pfizer
The company's revenue forecast has been lowered.
only about
67,000-71,000
million US dollars or a decrease of 33-29%
** Based on data from Pfizer Reports Record Full Year 2022 **
2. Moderna Company (Moderna):
Another company that made a lot of money during the COVID-19 epidemic from the mRNA formula vaccine in mid-January.
"Moderna Company"
has forecast revenue for the full year 2022 that should be approximately
18,400 million US dollars (about 6.1 billion baht, exchange rate as of February 7, 23).
If the company can actually achieve the targeted revenue
This will be a 0.54% drop in revenue from 2021, which was
$18.5 billion.
As for Moderna's 2023 revenue forecast, most analysts are expecting
The company's revenue should be reduced to only
7 billion US dollars (230 billion baht, exchange rate as of February 7, 23), or a drop of as much as 61%.
** Remark Moderna Company It is scheduled to report the results of the 4th quarter and summarize the results of the year 2022 on February 23, 2023 **
3. Johnson & Johnson Company (Johnson & Johnson)
for the income of
"Johnson & Johnson Company",
the owner of the COVID-19 vaccine, 1 injection formula, generates income throughout the
year 2022
at
US $ 94,943 million (approximately 3.1 trillion baht, exchange rate as of February 7) 23)
The revenue figure is
94,943 million US dollars.
is a higher number
Revenue in 2021, which was 93,775 million US dollars, about
1.3%!
Earnings per share were
$6.73, down 13.8% year over year.
As for the 2023 revenue forecast for
Johnson & Johnson
, the company initially predicted that
Sales of products and services exclude COVID-19 vaccines.
will grow at least 4%, however, most analysts expect the company's vaccine sales to drop by
80%!
** Based on Johnson & Johnson Reports Q4 and Full Year 2022 Results **
Why the 2023 revenue forecast has to be revised down :
Most analysts think
COVID-19 vaccine sales in 2023 are expected to drop by nearly two-thirds compared to last year.
Because at present, there are many countries that still have large stocks of vaccines, and the herd immunity of the people both from vaccination and infection with COVID-19
It has increased considerably during the mobilization period over the past 2 years.
which means
“Vaccine demand has gone downhill.”
When vaccine sales are expected to drop drastically this year
A pharmaceutical company that has earned exorbitant income over the past two years
Therefore, the business plan has been adjusted to accommodate
This is evident in Pfizer's announcement of its acquisition of
Global Blood Therapeutics
, a biopharmaceutical company
.
Long known for its technology to treat anemia at a value of $ 5.4
billion
and
Biohaven Pharmaceutical Company.
Renowned for innovative treatments for migraine.
with a value of up to
11.6 billion US dollars
Pfizer forecasts.
which has reduced the company's 2023 revenue figure to only about
67,000-71,000
million US dollars, or a decrease of 33-29%
, analysts still see that
This is an overly optimistic forecast compared to the current number of fully vaccinated populations.
As for the case
of "Moderna"
, in the eyes of analysts, it is quite worrisome.
That's because almost all of the company's revenue comes from COVID-19 vaccines.
Instead, it moved very little to prepare for new income.
To support income from the sale of vaccines that may decrease in 2023 or may drag on to 2024
And although the company expects minimum vaccine sales in 2023 to be
$5 billion
from previously confirmed futures contracts
excluding US sales
or new purchase contracts from Europe, Japan or other important markets
It also revealed progress in working with business partner
Merck
on the development of a cancer vaccine.
but overall
in the eyes of analysts
"Moderna"
continues to focus on revenue generated from COVID-19 vaccines.
Essentially, stay on as before.
In the case
of Johnson & Johnson
, analysts are likely to be more affected by the slump in sales of COVID-19 vaccines in 2023 than both
Pfizer and Moderate. Rna"
because it is expected that
Johnson & Johnson's vaccine sales are expected to drop as much as
80%
compared to 2022, in line with January's.
The company has announced a slowdown in the production of the COVID-19 vaccine.
The decline in sales in the fourth quarter was not as expected.
Thai Rath Online Specialized News Team reports
graphic Anon Chantanant
Read related news.
TECH GIANTS layoffs to cope with recession
behind the scenes clearance "Little Korean Ghosts" reveals 3 sources of gold mining for Thai workers, good income!
Why use spy balloons? The new China-U.S. dispute
Look at 4 businesses targeting gray money laundering
Chelsea champions transfer market and Financial Fair Play rules